Domača stranIMM • ASX
add
Immutep Ltd
Prejšnji trg. dan.
0,31 $
Dnevni razpon
0,30 $ - 0,32 $
Letni razpon
0,23 $ - 0,46 $
Tržna kapitalizacija
479,94 mio. AUD
Povprečni obseg
3,92 mio.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
ASX
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (AUD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 865,57 tis. | −4,89 % |
Stroški poslovanja | 2,03 mio. | −10,92 % |
Čisti dohodek | −10,74 mio. | −11,49 % |
Čista dobičkovnost prihodkov | −1,24 tis. | −17,23 % |
Earnings per share | — | — |
EBITDA | −11,21 mio. | −17,52 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (AUD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 181,88 mio. | 47,37 % |
Skupna sredstva | 201,58 mio. | 36,71 % |
Skupne obveznosti | 12,06 mio. | 9,82 % |
Celoten lastniški kapital | 189,52 mio. | — |
Shares outstanding | 1,45 mrd. | — |
Razmerje P/B | 2,38 | — |
Donosnost sredstev | −14,53 % | — |
Donosnost kapitala | −15,32 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (AUD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −10,74 mio. | −11,49 % |
Denar iz dejavnosti | −8,19 mio. | 30,16 % |
Denar iz naložb | −10,30 mio. | −87.445,92 % |
Denar iz financiranja | 47,81 mio. | 25,58 % |
Neto sprememba denarnih sredstev | 29,03 mio. | 5,47 % |
Prost denarni tok | −6,10 mio. | −44,31 % |
Vizitka
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
Generalni direktor
Datum ustanovitve
2001
Spletno mesto
Zaposleni
19
